Issue of Equity and Total Voting Rights

hVIVO plc

("hVIVO", the "Company" or the "Group")

Issue of Equity and Total Voting Rights

London, UK - 23 February 2026, hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces the issue of 1,386,991 new Ordinary Shares of £0.001 each in the Company ("First Consideration Shares") to three managers of Cryo-Store Limited ("Cryostore"). This issuance comprises the first tranche (50%) of the equity consideration payable pursuant to the acquisition of Cryostore announced on 27 February 2025 (the "Acquisition").

The remaining tranche of up to 1,386,991 new Ordinary Shares ("Second Consideration Shares") will be issued on the second anniversary of the Acquisition, subject to the individuals remaining in service of the Group.

Application has been made for the First Consideration Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective and trading will commence at 8.00am on 26 February 2026.

Total Voting Rights

Following admission, the Company will have 688,401,079 Ordinary Shares in issue. This figure of 688,401,079 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Notes to Editors

hVIVO plc (Ticker: HVO) is full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world's ten largest biopharma companies.

hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London-the largest of its kind worldwide. The company also offers comprehensive virology and immunology laboratory services under the hLAB brand.

Through its German subsidiary, CRS, hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector.

The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp. Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.